Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical study is to compare ulixacaltamide and placebo treatment in
essential tremor. The main question it aims to answer is:
• Is ulixacaltamide a safe and efficacious treatment for patients with essential tremor?
Participants will be asked to participate in one of two clinical studies where they will be
treated with either ulixacaltamide or placebo for a period of up to 12 weeks. After the
controlled study completion, they will be eligible to participate in a long-term, open-label
safety study and be treated with ulixacaltamide.